Home Cart Sign in  
Chemical Structure| 497061-48-0 Chemical Structure| 497061-48-0

Structure of DC_AC50
CAS No.: 497061-48-0

Chemical Structure| 497061-48-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

DC_AC50 is a dual inhibitor of Atox1 and CCS copper chaperones that can reduce or prevent acquired chemotherapy resistance by inhibiting intracellular copper chaperones, widely used in cancer chemotherapy resistance mechanism research.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of DC_AC50

CAS No. :497061-48-0
Formula : C17H12BrF2N3OS
M.W : 424.26
SMILES Code : NC1=C(SC2=NC3=C(C=C21)CCC3)C(NC4=C(C=C(C=C4Br)F)F)=O
MDL No. :MFCD03081557

Safety of DC_AC50

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P264-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P362-P403+P233-P501

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
H1299 cells 5, 10, 20 µM 24 h DC-AC50 treatment suppressed the viability of H1299 cells by inhibiting the ATOX1-mediated copper signaling pathway. BMC Pharmacol Toxicol. 2024 Aug 21;25(1):54
A549 cells 5, 10, 20 µM 24 h DC-AC50 treatment suppressed the viability of A549 and H1299 cells by inhibiting the ATOX1-mediated copper signaling pathway. BMC Pharmacol Toxicol. 2024 Aug 21;25(1):54
ARPE19 10 μM 24 h Evaluate the safety of DC_AC50 on normal cells, results showed minimal damage to normal cells Adv Sci (Weinh). 2021 Sep;8(18):e2004721
OM431 10 μM 24 h Evaluate the inhibitory effect of DC_AC50 on another UM cell type, results were similar to OCM1 cells Adv Sci (Weinh). 2021 Sep;8(18):e2004721
OCM1 10 μM 24 h Evaluate the inhibitory effect of DC_AC50 on UM cells, results showed the lowest cell viability (21%) in CP@Au@DC_AC50 +NIR group Adv Sci (Weinh). 2021 Sep;8(18):e2004721

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c nude mice A549 cell-induced tumor model Intraperitoneal injection 20 mg/kg Once daily for 21 days DC-AC50 treatment suppressed tumor growth by inhibiting the ATOX1-mediated copper pathway. BMC Pharmacol Toxicol. 2024 Aug 21;25(1):54
Mice UM orthotopic model Eyeball injection 100 μM 3 consecutive days, 5 min each time Evaluate the antitumor effect of CP@Au@DC_AC50 +NIR in vivo, results showed significant tumor inhibition and eyeball appearance similar to the normal group Adv Sci (Weinh). 2021 Sep;8(18):e2004721

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.36mL

0.47mL

0.24mL

11.79mL

2.36mL

1.18mL

23.57mL

4.71mL

2.36mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records